Remus PharmaceuticalsNSE:REMUS -1.04%61 Return-on-Tangible-Equity is 12.18% as of Mar. 2026, which is 62% below its 10-year median of 32.32. GuruFocus rates NSE:REMUS with a GF Score™ of 61/100 and a GF Value™ of ₹2,071.36 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 111 Medical Distribution companies, Remus Pharmaceuticals ranks better than 63.06% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Remus Pharmaceuticals's annualized net income for the quarter that ended in Mar. 2026 was ₹390 Mil. Remus Pharmaceuticals's average shareholder tangible equity for the quarter that ended in Mar. 2026 was ₹3,201 Mil. Therefore, Remus Pharmaceuticals's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 12.18%.
The historical rank and industry rank for Remus Pharmaceuticals's Return-on-Tangible-Equity or its related term are showing as below:
NSE:REMUS'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 12.51 Med: 32.32 Max: 71.44
Current: 12.51
During the past 7 years, Remus Pharmaceuticals's highest Return-on-Tangible-Equity was 71.44%. The lowest was 12.51%. And the median was 32.32%.
NSE:REMUS's Return-on-Tangible-Equity is ranked better than 63.06% of 111
companies
in the Medical Distribution industry
Industry Median: 8.81
vs NSE:REMUS: 12.51
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Remus Pharmaceuticals Return-on-Tangible-Equity Related Terms
Remus Pharmaceuticals Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Remus Pharmaceuticals's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:REMUS vs MCK, CAH, COR: Return-on-Tangible-Equity Comparison
For the Medical Distribution subindustry, Remus Pharmaceuticals's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Remus Pharmaceuticals Return-on-Tangible-Equity vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Remus Pharmaceuticals's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Remus Pharmaceuticals's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 12.18% mean?
Remus Pharmaceuticals (NSE:REMUS) has a Return-on-Tangible-Equity of 12.18% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Remus Pharmaceuticals and its competitors. This is 62% below median its historical median of 32.32. Over the past decade, Remus Pharmaceuticals' Return-on-Tangible-Equity has ranged from 12.51 to 71.44. According to the industry distribution chart, Remus Pharmaceuticals ranks #41 out of 111 companies in the Medical Distribution industry, placing it in the top 36.9%.
Is Remus Pharmaceuticals' Return-on-Tangible-Equity too high?
Remus Pharmaceuticals' current Return-on-Tangible-Equity of 12.18% is 62% below median its 10-year median of 32.32. Over the past 10 years, this metric has ranged from a low of 12.51 to a high of 71.44. The Medical Distribution industry median Return-on-Tangible-Equity is 8.81. Remus Pharmaceuticals' value of 12.18% is 38.3% above this industry median. Based on the distribution chart, Remus Pharmaceuticals ranks #41 out of 111 companies in the Medical Distribution industry, which is above the industry midpoint. Overall, Remus Pharmaceuticals has a GF Score™ of 61/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Remus Pharmaceuticals' Return-on-Tangible-Equity compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Remus Pharmaceuticals ranks #41 out of 111 companies for Return-on-Tangible-Equity. This puts Remus Pharmaceuticals in the upper half of its industry. The industry median Return-on-Tangible-Equity is 8.81. Remus Pharmaceuticals' value of 12.18% is 38.3% above this benchmark. Historically, Remus Pharmaceuticals' own Return-on-Tangible-Equity has ranged from 12.51 to 71.44 over the past decade. While the company's 10-year median is 32.32 vs. the industry median of 8.81, Remus Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Distribution company?
The median Return-on-Tangible-Equity among Medical Distribution companies is 8.81, based on 111 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Remus Pharmaceuticals's current Return-on-Tangible-Equity of 12.18% is 38.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Remus Pharmaceuticals and its competitors. For the Medical Distribution industry, the median Return-on-Tangible-Equity is 8.81 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Remus Pharmaceuticals's current Return-on-Tangible-Equity is 12.18%, which is 62% below median its own 10-year median of 32.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Remus Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Remus Pharmaceuticals (NSE:REMUS) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹2,071.36, compared to a current price of ₹739.95 — trading 64.3% below its estimated fair value. The current Return-on-Tangible-Equity is 12.18%, which is 62% below median its 10-year median of 32.32 and 38.3% above the Medical Distribution industry median of 8.81. Remus Pharmaceuticals' overall GF Score™ is 61/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Remus Pharmaceuticals (NSE:REMUS), the current Return-on-Tangible-Equity is 12.18% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Remus Pharmaceuticals (NSE:REMUS) Overvalued in 2026?
Based on GuruFocus' analysis, Remus Pharmaceuticals stock appears to be undervalued.
The current stock price of ₹739.95 is trading 64.3% below its estimated GF Value™ of ₹2,071.36.
GuruFocus considers Remus Pharmaceuticals to be Significantly Undervalued.
Key valuation signals for NSE:REMUS:
Return-on-Tangible-Equity: 12.18% (62% below median its 10-year median of 32.32)
GF Value™: ₹2,071.36 vs. price of ₹739.95 (64.3% below fair value)
Industry Position: 38.3% above the Medical Distribution median (#41 of 111)
No single metric tells the full story. See the NSE:REMUS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Remus Pharmaceuticals Ltd is engaged in the marketing & distribution of finished formulations of pharmaceutical drugs. The company also deals in API (Active Pharmaceutical Ingredient). It also provides technical consultancy services to various distributors for the preparation of reports on the dossiers of the products to be registered by them in various countries. Remus Pharmaceuticals market niche medicinal combinations. It exports generic drugs by conducting intensive market research in the pharmaceutical industry to expand its product portfolio.
61GF Score
Get the complete analysis for NSE:REMUS
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:REMUS has been successfully added to your 
